News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Bitcoin Price Rise: Unveiling the Potential for an Explosive Rally
BitcoinWorld·2025/07/29 21:10
Market Volatility Alert: Trump’s Ultimatum to Russia and Its Global Economic Ripple
BitcoinWorld·2025/07/29 21:10
MicroStrategy Bitcoin: A Bold $2.52 Billion Acquisition Reshapes Corporate Crypto Strategy
BitcoinWorld·2025/07/29 21:10
Urgent: Market Downturn Drags US Stocks Lower – What Does It Mean for Your Crypto?
BitcoinWorld·2025/07/29 21:10
Crypto ETPs: Unlocking Revolutionary In-Kind Transactions
BitcoinWorld·2025/07/29 21:10
Altcoins update: Dogecoin and Injective signal recoveries as Ethereum eyes $4,000
Coinjournal·2025/07/29 21:10
Synagistics Launches Digital Finance Group for Stablecoins and Tokenization
Synagistics Limited has launched Synagistics Digital Finance Group (SDFG), a new division focused on developing interoperable multi-currency stablecoins and real-world asset tokenization solutions to accelerate Asia’s digital finance infrastructure, according to Hong Kong Business.
DeFi Planet·2025/07/29 21:10
Hong Kong Finalizes Stablecoin Regulations, Sets August 1 as Launch Date for New Framework
The Hong Kong Monetary Authority (HKMA) has officially rolled out its regulatory framework for stablecoin issuers, marking a major step in the city’s effort to regulate digital assets.
DeFi Planet·2025/07/29 21:10
JD.com Registers Stablecoin Entities Ahead of Hong Kong’s New Regulations
China’s e-commerce heavyweight JD.com has taken strategic steps toward launching a stablecoin, just days before Hong Kong’s new regulatory framework for stablecoin issuers comes into force.
DeFi Planet·2025/07/29 21:10
What You Say to ChatGPT Could Be Used Against You in Court
Cointribune·2025/07/29 21:05
Flash
12:56
Spot Gold Drops $14 in Short-Term Spot gold has fallen $14 in the short term, declining over 1.00% during the day, currently reported at $4133.10 per ounce. (Jin Shi)
12:51
Vivos (OTC market code: RDGL) has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) and will initiate a human clinical feasibility study of its Radiogel® Precision Radionuclide Therapy™.This approval marks a key step forward for the clinical application of this innovative therapy, allowing the company to begin initial safety and feasibility assessments in humans. The Radiogel® technology is designed to enable precise radiation treatment within tumors and is expected to provide a new treatment option for cancer patients. The approved clinical study will collect essential data to lay the foundation for larger-scale clinical trials in the future.
12:51
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level.This positive safety data lays the foundation for further exploration of higher doses and demonstrates the potential of this therapy in terms of patient tolerability.
News